Max Healthcare, healthcare services company in India, and Anuva, a genomics biotech company, today announced that they have entered into a Memorandum of Understanding (MoU) to conduct genomic-based research on various communicable and non-communicable diseases in India.
The objective of the research will be to identify insights for precision medicine application across diseases including breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, drug resistant tuberculosis, and others, the statement by the company stated.
As part of the five-year engagement, Max Healthcare will provide its expertise in clinical research and will serve as the clinical center for data and/or sample collection from individuals who consent to share their data for the purpose of research, said the company.
On signing of the MoU, Dr. Sandeep Budhiraja, Group Medical Director from Max Healthcare said, “There is a lot to discover in the field of genetic and lifestyle diseases. With the coming of precision medicine and genomics, it has the potential to provide efficient solutions and transform the way we look at modern medicine today. ”
Dr. Jonathan Picker, Chief Executive Officer from Anuva, said, “The promise and potential of genomics to transform medicine is enormous. The opportunity to work with Max Healthcare is extremely important, as they bring great expertise in diagnostics, treatment and clinical research across the disease spectrum. Together, we can help to make personalised precision care a reality and we are tremendously excited to collaborate with Max Healthcare.”
Apart from research, the institutions will also explore the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer for cross-learning and capacity building in the fields of biomedical science and arenas of public health, the statement read.
The partnership will also facilitate knowledge sharing and communication among scientists, epidemiologists and other stakeholders having mutual interest in the discipline, company added.